Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced that its management team will present at the Stifel Virtual Healthcare Conference on November 16, 2020, at 9:20 a.m. ET, and the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 6:45 p.m. GMT (1:45 p.m. ET). The presentations will focus on FT218, an investigational formulation of sodium oxybate aimed at treating excessive daytime sleepiness and cataplexy in narcolepsy patients. Webcasts will be accessible on the company's website and available for replay for 90 days post-presentation.

DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the Stifel Virtual Healthcare Conference and the Jefferies Virtual London Healthcare Conference that are being held in November 2020.

Event:	Stifel 2020 Virtual Healthcare Conference
Date:	Monday, November 16
Time:	9:20 a.m. ET
Webcast:	A webcast will be available at the “Investors” section of the Company’s website at www.avadel.com. A replay of the webcasts will be available on Avadel’s website for 90 days following the presentation.
Event:	Jefferies Virtual London Healthcare Conference
Date:	Wednesday, Nov. 18th
Time:	6:45 p.m. GMT (1:45 p.m. ET)
Webcast:	A webcast will be available at the “Investors” section of the Company’s website at www.avadel.com. A replay of the webcasts will be available on Avadel’s website for 90 days following the presentation.

About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.

Contacts:

Tom McHugh
Chief Financial Officer
Phone: (636) 449-1843
Email: tmchugh@avadel.com
        
Tim McCarthy
LifeSci Advisors, LLC
Phone: (212) 915.2564
Email: tim@lifesciadvisors.com

FAQ

What is the date and time of Avadel Pharmaceuticals' presentation at the Stifel Virtual Healthcare Conference?

Avadel Pharmaceuticals will present on November 16, 2020, at 9:20 a.m. ET.

When is Avadel Pharmaceuticals presenting at the Jefferies Virtual London Healthcare Conference?

Avadel Pharmaceuticals will present on November 18, 2020, at 6:45 p.m. GMT (1:45 p.m. ET).

What is FT218 and its purpose in relation to Avadel Pharmaceuticals?

FT218 is an investigational, once-nightly formulation of sodium oxybate developed by Avadel to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Where can I find the webcasts of Avadel Pharmaceuticals' presentations?

The webcasts will be available in the 'Investors' section of Avadel Pharmaceuticals' website, with replays accessible for 90 days after the presentations.

What is the stock symbol for Avadel Pharmaceuticals?

The stock symbol for Avadel Pharmaceuticals is AVDL.